$3.12-0.01 (-0.32%)
News25/Ratings0
Price$3.12-0.36 (-10.34%)
2026-01-162026-04-22
News · 26 weeks35-25%
2025-10-262026-04-19
Mix990d
- SEC Filings5(56%)
- Other2(22%)
- Earnings1(11%)
- Offering1(11%)
Latest news
25 items- SECSEC Form 10-K filed by Imunon Inc.10-K - Imunon, Inc. (0000749647) (Filer)
- SECImunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 StudyIMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest from principal investigators and the medical community Company to hold conference call today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunother
- PRIMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian CancerThe increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated with PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated median increase in OS of 24.2 months Enrollment in IMUNON's Phase 3 pivotal trial for IMNN-001 remains ahead of plan, supported by continued strong interest from investigators and medical community LAWRENCEVILLE, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced final cl
- PRIMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1
- SECImunon Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form 424B5 filed by Imunon Inc.424B5 - Imunon, Inc. (0000749647) (Filer)
- SECImunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDYStrategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing LAWRENCEVILLE, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced a strategic reorganization that will eliminate headcount not essential to the Phase 3 trial and redefine the job descriptions for additional employees to reduce operating expenses while supporting the co
- INSIDERNew insider Church Jeffrey Wayne claimed ownership of 26 shares (SEC Form 3)3 - Imunon, Inc. (0000749647) (Issuer)
- SECImunon Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- INSIDERSEC Form 4 filed by CFO Bragg Kimberly4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Anwer Khursheed4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Director Fritz Frederick J.4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Faller Douglas Vincent4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by General Counsel and Corp Sec Eylward Susan4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Director Pellizzari Christine A4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Director Braun Donald P4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Director Dentzer James E4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by Executive Chairman of Board Tardugno Michael H4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Lindborg Stacy4 - Imunon, Inc. (0000749647) (Issuer)
- SECSEC Form 424B5 filed by Imunon Inc.424B5 - Imunon, Inc. (0000749647) (Filer)
- SECImunon Inc. filed SEC Form 8-K: Other Events8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ RulesLAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,939,114 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate of 1,939,114 shares of common stock, in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock (or pre-funded warrant in-lieu thereof) is being sold together with one warrant to purchase one share of c
- PRIMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILLE, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN) Dear Valued Shareholders, 2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON's position. Our focus on harnessing the power to activate the body's immune system against cancer has yielded com